SAN FRANCISCO – For a moment at the biggest biotech conference of the year, drug companies found themselves lambasted by one of their own.

“We’ve done all these great things, yet we’re hated,” Regeneron CEO Leonard Schleifer said during his presentation at the JPMorgan Healthcare Investor Conference. “We talk about doing things right, but I’m going to tell you I don’t think we do.”